PHMMF 財務： Pharma Mar SA AI 分析

Q: Pharma Mar SA 的關鍵財務報表是什麼？

根據最新的財務報表（Form-10K），Pharma Mar SA 的總資產為 $349，淨利潤為 $26

Q: PHMMF 的關鍵財務比率是什麼？

Pharma Mar SA 的流動比率為 2.47，淨利潤率為 14.94，每股銷售為 $9.9。

Q: Pharma Mar SA 的收入按細分市場或地理位置如何劃分？

Pharma Mar SA 最大收入來源為 Oncology，在最近的收益報告中收入為 156,841,000。就地區而言，Ireland 是 Pharma Mar SA 的主要市場，收入為 75,356,000。

Q: Pharma Mar SA 是否盈利？

是的，根據最新的財務報表，Pharma Mar SA 的淨利潤為 $26

Q: Pharma Mar SA 有負債嗎？

是的，Pharma Mar SA 的負債為 141

Q: Pharma Mar SA 的流通股有多少？

Pharma Mar SA 的總流通股為 17.57

首頁

股票

PHMMF

PHMMF 財務

Pharma Mar SA

$90.21

收盤價：Jan 16, 16:00:00 GMT-5

$90.21

盤後：Jan 16, 20:00:00 GMT-5

概觀預測收益股利財務狀況

收入

資產負債表

現金流量

年度

每季

PHMMF 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	179	174	158	196	229	269
營收年增率 (YoY)	7%	10%	-19%	-14%	-15%	216%
營收成本	9	8	9	13	16	13
毛利	169	166	148	182	213	256
銷售、一般及管理費用	55	45	40	41	38	34
研發	97	100	97	81	70	50
營業費用	147	160	152	138	121	100
其他非營業收入 (費用)	--	5	4	0	0	0
稅前淨利	24	11	-3	43	95	145
所得稅費用	-9	-14	-4	-5	2	8
淨利	34	26	1	49	92	137
淨利成長	--	2,500%	-98%	-47%	-33%	-1,345%
稀釋後流通股數	17.53	17.56	17.91	18.06	18.08	18.32
股數年變動 (YoY)	0%	-2%	-1%	0%	-1%	-1%
每股盈餘 (稀釋)	1.93	1.48	0.06	2.73	5.13	7.49
每股盈餘成長率	5,671%	2,379%	-98%	-47%	-32%	-1,328%
自由現金流	16	-9	-29	29	17	275
每股自由現金流	--	--	--	--	--	--
毛利率	94.41%	95.4%	93.67%	92.85%	93.01%	95.16%
營業利益率	12.29%	3.44%	-2.53%	22.44%	40.17%	57.99%
淨利率	18.99%	14.94%	0.63%	25%	40.17%	50.92%
自由現金流利潤率	8.93%	-5.17%	-18.35%	14.79%	7.42%	102.23%
EBITDA	30	12	1	49	97	163
EBITDA 利潤率	16.75%	6.89%	0.63%	25%	42.35%	60.59%
EBITDA 中的折舊與攤銷	8	6	5	5	5	7
EBIT	22	6	-4	44	92	156
EBIT 利潤率	12.29%	3.44%	-2.53%	22.44%	40.17%	57.99%
有效稅率	-37.5%	-127.27%	133.33%	-11.62%	2.1%	5.51%

Follow-Up Questions

Pharma Mar SA 的關鍵財務報表是什麼？



PHMMF 的關鍵財務比率是什麼？



Pharma Mar SA 的收入按細分市場或地理位置如何劃分？



Pharma Mar SA 是否盈利？



Pharma Mar SA 有負債嗎？



Pharma Mar SA 的流通股有多少？



關鍵數據

前收市價

$90.21

開盤價

$93

當日範圍

$90.21 - $93

52週區間

$80.91 - $110.4

交易量

152

平均成交量

每股盈餘 (TTM)

2.29

股息收益率

市值

$1.5B

什麼是 PHMMF？

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 500 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.

功能特性

交易策略